MAM
NVCT icon

Martingale Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Martingale Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
+18,024
New +$154K ﹤0.01% 785

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Martingale Asset Management's NVCT Position: Q1 2026 in Review

Martingale Asset Management opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 18,024 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #785 among its holdings.

62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Martingale Asset Management held 18,024 shares of Nuvectis Pharma worth $139K as of Q1 2026.
  • Nuvectis Pharma was a new Martingale Asset Management position in Q1 2026.
  • Nuvectis Pharma made up ﹤0.01% of Martingale Asset Management's portfolio in Q1 2026, its #785 holding.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.